Ozurdex (dexamethasone intravitreal implant) / AbbVie - LARVOL DELTA

EFFICACY OF COMBINED DEXAMETHASONE IMPLANT AND NAVIGATED SUBTHRESHOLD MICROPULSE YELLOW LASER IN DIABETIC MACULAR EDEMA. (PubMed, Retina) - "Within the 12-month follow-up period, sequential navigated SMLT performed four weeks after dexamethasone implantation was associated with improvements in visual and anatomical outcomes and with a longer retreatment-free interval compared with dexamethasone monotherapy, without additional safety concerns."

Journal • Diabetic Macular Edema • Ophthalmology

Evaluation of the Effects of Intravitreal Application of an Ozurdex Implant in Patients with Macular Edema due to Retinal Vein Occlusion. (PubMed, Cesk Slov Oftalmol) - "Our results indicate that Ozurdex is a safe and effective second-line treatment for macular edema (ME) due to RVO. In our group, the best functional and anatomical results were achieved two months after application. By the fourth month, a decline in BCVA and an increase in CRT were observed. Between the fifth and sixth month, retreatment was necessary in some patients. Additionally, we confirmed that the greatest rise in IOP occurred two months post-application, which resolved spontaneously by the sixth month. In four patients, IOP values above 30 mmHg were recorded during follow-up, and the intraocular pressure was managed with medication."

Journal • Retrospective data • Macular Edema • Ophthalmology • Retinal Disorders • Retinal Vein Occlusion

DECADE: Efficacy Comparison of DExamethasone Intravitreal Implant Combined With Aflibercept Versus Aflibercept Monotherapy in Treatment-naïve Inflammatory Diabetic Macular Edema Patients (clinicaltrials.gov) - P4 | N=114 | Not yet recruiting | Sponsor: Kun Liu

Monotherapy • New P4 trial • Diabetic Macular Edema • Ophthalmology

SELVEDge: Selinexor, Venetoclax, and Dexamethasone (XVenD) in t(11;14)-Positive Relapsed/Refractory Multiple Myeloma (clinicaltrials.gov) - P2 | N=33 | Recruiting | Sponsor: University of Miami | Trial completion date: Mar 2028 ➔ Mar 2030 | Trial primary completion date: Mar 2026 ➔ Mar 2028

Trial completion date • Trial primary completion date • Hematological Malignancies • Multiple Myeloma • Oncology

Anterior migration of Ozurdex® implant. (PubMed, J Fr Ophtalmol) - No abstract available

Journal

Acute Retinal Detachment Following Ozurdex Implant in a Nonvitrectomized Eye. (PubMed, Case Rep Ophthalmol Med) - "Here, we report a case of a 53-year-old male with a history of lymphoma (treated with chemotherapy in 2016 and currently on Cellcept and low-dose oral prednisolone), diabetes mellitus (DM), hypertension (HTN), and hyperlipidemia, who presented shortly after intravitreal Ozurdex injection in the left eye with retinal detachment (RD). Ozurdex is a valuable option for treatment of chronic diabetic macular edema (DME). This case highlights the need for a high index of suspicion for retinal detachment in pseudophakic patients with compromised retina, even after seemingly routine Ozurdex injection."

Journal • Cardiovascular • Diabetes • Diabetic Macular Edema • Dyslipidemia • Hematological Malignancies • Hypertension • Lymphoma • Metabolic Disorders • Ocular Infections • Ocular Inflammation • Oncology • Ophthalmology • Retinal Disorders

Sustained Intraocular Pressure Control After iStent Infinite® Implantation for Steroid-Induced Glaucoma: A Case Report. (PubMed, J Clin Med) - " This is the first reported case of SIG-associated Ozurdex successfully managed with triple trabecular micro-bypass stents. The iStent infinite implantation provided safe and sustained IOP control for SIG, highlighting its potential role in patients requiring continuous intravitreal steroids."

Journal • Cardiovascular • Glaucoma • Macular Edema • Ophthalmology • Retinal Disorders • Retinal Vein Occlusion

Atypical Acute Inflammatory Reaction after Intravitreal Dexamethasone Implant: A Case of Sterile Endophthalmitis. (PubMed, Arch Soc Esp Oftalmol (Engl Ed)) - "The implant showed an abnormal appearance-swollen and surrounded by vitreous condensations-suggesting possible structural alterations of the device or inadvertent contamination during injection, which could have triggered an immunologic or irritative reaction, among other mechanisms described in the literature. This case highlights the importance of recognizing atypical presentations of intraocular inflammation following Ozurdex®, differentiating them from infectious processes, and reporting such events to pharmacovigilance systems, given that this is an exceptional reaction with very few cases reported in the literature."

Journal • Inflammation • Macular Edema • Ocular Infections • Ocular Inflammation • Ophthalmology • Uveitis

Early Switch to Dexamethasone Intravitreal Implant in Patients with Diabetic Macular Edema Poorly Responding to Anti-VEGF Therapy: A Narrative Review. (PubMed, Ophthalmol Ther) - "Evidence from several studies indicates that an early switch can be associated with better visual and anatomic outcomes compared with delayed intervention. This narrative review synthesizes current data on the use of dexamethasone intravitreal implant for DME, with particular emphasis on patients with a suboptimal response to anti-VEGF therapy switching early to corticosteroid treatment."

Journal • Review • CNS Disorders • Diabetic Macular Edema • Diabetic Retinopathy • Ophthalmology • Retinal Disorders

Observational Study of Adult Participants With Diabetic Macular Edema and Suboptimal Response to Anti-Vascular Endothelial Growth Factor Treated With Dexamethasone Intravitreal Implant (clinicaltrials.gov) - P=N/A | N=236 | Active, not recruiting | Sponsor: AbbVie | Recruiting ➔ Active, not recruiting

Enrollment closed • Diabetic Macular Edema • Ophthalmology

A Study of Selinexor, in Combination With Carfilzomib, Daratumumab or Pomalidomide in Patients With Multiple Myeloma (clinicaltrials.gov) - P2 | N=96 | Suspended | Sponsor: Hackensack Meridian Health | Trial completion date: Jan 2026 ➔ Feb 2027 | Trial primary completion date: Jan 2026 ➔ Feb 2027

Trial completion date • Trial primary completion date • Hematological Malignancies • Multiple Myeloma • Oncology

Ozurdex® Implant Inside the Capsular Bag: A Report of a Rare Case. (PubMed, Cureus) - "Postoperatively, the implant was visualized within the capsular bag, confirmed by anterior segment optical coherence tomography. This rare event highlights an unusual complication of intravitreal Ozurdex injection and emphasizes the importance of technique and anatomical considerations during administration."

Journal • Cataract • Ocular Inflammation • Ophthalmology • Uveitis

Endophthalmitis After Dexamethasone Implant. (PubMed, Clin Exp Ophthalmol) - "The rate of dexamethasone implant-related endophthalmitis is 0.16% which is higher than other intravitreal injections reported in the literature, with considerably poor visual outcomes. The vitreous diagnostic samples are culture-positive in 87% of cases (13/15), with 46.7% (7/15) isolating Staphylococcus epidermidis."

Journal • Ocular Infections • Ocular Inflammation • Ophthalmology • Retinal Disorders

Short-Term Results of Dexamethasone Intravitreal Implant in Patients with Persistent Diabetic Macular Edema. (PubMed, Niger J Clin Pract) - "IVDI demonstrated substantial enhancement in patients with chronic persistent DME who were resistant to different treatments, with peak efficacy observed in the second month. Therefore, it may be considered an alternative therapeutic choice."

Journal • Diabetic Macular Edema • Diabetic Retinopathy • Ophthalmology • Retinal Disorders

The impact of aflibercept combined with dexamethasone intravitreal implant on visual function and aqueous humor inflammatory responses in diabetic macular edema. (PubMed, Pak J Pharm Sci) - "These findings underscore the potential of AFL combined with DEX intravitreal implant to enhance visual outcomes and modulate intraocular inflammation in DME patients, highlighting its substantial clinical utility."

Journal • Diabetic Macular Edema • Inflammation • Ophthalmology • IL1B • IL6

Anterior Chamber Migration of Dexamethasone Implant in a Patient Implanted with Carlevale Sutureless Scleral Fixation Intraocular Lens: A Case Report. (PubMed, Case Rep Ophthalmol) - "To report a case of anterior chamber migration of the dexamethasone intravitreal implant (DEX-I) through a new type of scleral fixated lens, the Carlevale® intraocular lens (IOL) (Cutting Edge, Italy)...Migration of the DEX-I into the anterior chamber remains a potential complication in vitrectomized eyes with capsular defects, even with the use of scleral-fixated IOLs such as the Carlevale®, which features a large optic. This highlights the importance of careful patient selection and postoperative monitoring in such cases."

Journal • Macular Edema • Ophthalmology • Retinal Vein Occlusion

Intravitreal Dexamethasone Implant in Retinal Vein Occlusion: A Pilot Study Exploring Baseline Ocular and Circulating Biomarkers. (PubMed, Int J Mol Sci) - "Ozurdex was effective in real-life RVO treatment, particularly in BRVO. Serum XO and TSP-1 may serve as prognostic biomarkers for RVO."

Biomarker • Journal • Retinal Disorders • Retinal Vein Occlusion • THBS1

Treatment of choroidal melanoma-associated exudative retinal detachments with a dexamethasone intravitreal implant prior to proton beam radiation. (PubMed, Retin Cases Brief Rep) - "Improved clinical outcomes were not observed in patients receiving the dexamethasone implant prior to proton radiation. No new safety concerns were identified with the use of dexamethasone in this cohort."

Journal • Cataract • Choroidal Melanomas • Melanoma • Ocular Melanoma • Oncology • Ophthalmology • Retinal Disorders • Solid Tumor

Efficacy of dexamethasone intravitreal implant combined with anti-VEGF drugs in the treatment of diabetic macular edema: a systematic review and meta-analysis. (PubMed, Front Endocrinol (Lausanne)) - "DEX combined with anti-VEGF agents confers superior anatomical outcomes in reducing CMT compared to anti-VEGF monotherapy in the management of DME. However, further large-scale, multicenter randomized controlled trials with extended follow-up are warranted to validate these findings and optimize treatment protocols."

Clinical • Journal • Retrospective data • Review • Diabetes • Diabetic Macular Edema • Metabolic Disorders • Ophthalmology

Effectiveness of aflibercept, ranibizumab, and Ozurdex for treating diabetic macular edema showing a suboptimal response: A comparative observational study. (PubMed, Taiwan J Ophthalmol) - "Resistance to anti-VEGF occurs in a substantial proportion of patients with DME. Few studies compare the efficacy of anti-VEGF agents and steroid therapy as second-line treatment for DME to determine the best treatment strategy. Injections of the examined drugs provide a similar clinical benefit. The increase in IOP following steroid injections compared to anti-VEGF agents is well known and has been previously described. It should be well considered before selecting second-line treatment."

Journal • Observational data • Diabetes • Diabetic Macular Edema • Diabetic Retinopathy • Metabolic Disorders • Ophthalmology • Retinal Disorders

A retrospective study reporting the incidence, risk factors, and intraocular pressure rise in patients receiving intravitreal steroids for retinal inflammatory diseases in a tertiary eye care hospital of South India. (PubMed, Indian J Ophthalmol) - "We found that the incidence of SI-OHT was higher in IVTA group as compared to DEX group. No dose-dependent incidence was observed in the case of IVTA group. Age, gender, number of injections, and myopia were not associated with the risk of SI-OHT. Renal disease showed a significant association with the risk of SI-OHT in the DEX group, and patients with TB, stroke, and other drug allergies experienced a fivefold greater increase in IOP values in those groups."

Journal • Retrospective data • Allergy • Cardiovascular • Diabetic Macular Edema • Glaucoma • Immunology • Inflammation • Nephrology • Ocular Inflammation • Ophthalmology • Renal Disease

Choroidal Detachment Secondary to Scleral Wound Leak After Ozurdex® Implantation in an Eye With Previous Vitrectomy: A Case Report. (PubMed, Cureus) - "Early detection through Seidel testing and prompt surgical repair are crucial to preventing sight-threatening complications. Preventive measures, particularly injection-site rotation, careful post-injection wound assessment, and lower thresholds for suturing in high-risk eyes, are vital in long-term Ozurdex management."

Journal • Glaucoma • Macular Edema • Ophthalmology • Pain • Retinal Vein Occlusion

Pharmacokinetic model for drug delivery by Ozurdex. (PubMed, Drug Deliv Transl Res) - "The drug depot in the lens eventually releases the drug back into vitreous humor, which increases the total duration over which the concentrations are efficacious. The model can be applied to other sustained release devices placed in vitreous humor or elsewhere in the eye."

Journal • PK/PD data

Long Term of Follow-Up of Melanoma-Associated Retinopathy: A Case Report. (PubMed, Ocul Immunol Inflamm) - "A 48-year-old man with stage IV cutaneousmelanoma with BRAF V600E mutation achieved complete systemic remission with vemurafenib...Sub-Tenon's triamcinolone and intravenous immunoglobulin failed toimprove symptoms, but bilateral intravitreal dexamethasone implants (Ozurdex) resolved visual disturbances and normalized ERG...The absence of autoantibodies and late flares challenges current diagnostic paradigms, emphasizing ERG's critical role. Proactive ophthalmologic surveillance and individualized local therapy canpreserve vision in this underrecognized condition."

Journal • Cutaneous Melanoma • Immunology • Melanoma • Ocular Melanoma • Oncology • Ophthalmology • Retinal Disorders • Solid Tumor • BRAF

AFT-41: Study of Lenalidomide/Ixazomib/Dexamethasone/Daratumumab in Transplant-Ineligible Patients With Newly Diagnosed MM (clinicaltrials.gov) - P2 | N=79 | Active, not recruiting | Sponsor: Alliance Foundation Trials, LLC. | Trial completion date: Jul 2026 ➔ Jun 2027 | Trial primary completion date: Oct 2025 ➔ Dec 2026

Trial completion date • Trial primary completion date • Hematological Malignancies • Multiple Myeloma • Oncology • Transplantation